CRISPR-Phage Antibacterials: Scientific, Economic, and Regulatory Challenges

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

CRISPR-Phage Antibacterials: Scientific, Economic, and Regulatory Challenges. / Pacia, Danielle M.; Brown, Beatrice L.; Minssen, Timo; Darrow, Jonathan.

I: Journal of Law and the Biosciences, Bind 11, Nr. 1, 26.01.2024.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Pacia, DM, Brown, BL, Minssen, T & Darrow, J 2024, 'CRISPR-Phage Antibacterials: Scientific, Economic, and Regulatory Challenges', Journal of Law and the Biosciences, bind 11, nr. 1. https://doi.org/10.1093/jlb/lsad030

APA

Pacia, D. M., Brown, B. L., Minssen, T., & Darrow, J. (2024). CRISPR-Phage Antibacterials: Scientific, Economic, and Regulatory Challenges. Journal of Law and the Biosciences, 11(1). https://doi.org/10.1093/jlb/lsad030

Vancouver

Pacia DM, Brown BL, Minssen T, Darrow J. CRISPR-Phage Antibacterials: Scientific, Economic, and Regulatory Challenges. Journal of Law and the Biosciences. 2024 jan. 26;11(1). https://doi.org/10.1093/jlb/lsad030

Author

Pacia, Danielle M. ; Brown, Beatrice L. ; Minssen, Timo ; Darrow, Jonathan. / CRISPR-Phage Antibacterials: Scientific, Economic, and Regulatory Challenges. I: Journal of Law and the Biosciences. 2024 ; Bind 11, Nr. 1.

Bibtex

@article{40f11b3c34f2426280fa27258aa60d6b,
title = "CRISPR-Phage Antibacterials: Scientific, Economic, and Regulatory Challenges",
abstract = "Antibiotic resistance is one of the most dangerous threats to public health. The use of viruses to kill bacteria—phage therapy—has been used for nearly a century but has only recently risen to the forefront of discussion as a potential non-traditional antibacterial that can help to address antibiotic resistant infections. Phage therapy can be augmented using CRISPR (clustered regularly interspaced short palindromic repeats) for tailored bacterial killing. This article assesses the potential of CRISPR-enhanced phage therapy as a product that can address antibiotic resistance, focusing on the economic, legal, and regulatory challenges to its development and availability",
author = "Pacia, {Danielle M.} and Brown, {Beatrice L.} and Timo Minssen and Jonathan Darrow",
year = "2024",
month = jan,
day = "26",
doi = "https://doi.org/10.1093/jlb/lsad030",
language = "English",
volume = "11",
journal = "Journal of Law and the Biosciences",
issn = "2053-9711",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - CRISPR-Phage Antibacterials: Scientific, Economic, and Regulatory Challenges

AU - Pacia, Danielle M.

AU - Brown, Beatrice L.

AU - Minssen, Timo

AU - Darrow, Jonathan

PY - 2024/1/26

Y1 - 2024/1/26

N2 - Antibiotic resistance is one of the most dangerous threats to public health. The use of viruses to kill bacteria—phage therapy—has been used for nearly a century but has only recently risen to the forefront of discussion as a potential non-traditional antibacterial that can help to address antibiotic resistant infections. Phage therapy can be augmented using CRISPR (clustered regularly interspaced short palindromic repeats) for tailored bacterial killing. This article assesses the potential of CRISPR-enhanced phage therapy as a product that can address antibiotic resistance, focusing on the economic, legal, and regulatory challenges to its development and availability

AB - Antibiotic resistance is one of the most dangerous threats to public health. The use of viruses to kill bacteria—phage therapy—has been used for nearly a century but has only recently risen to the forefront of discussion as a potential non-traditional antibacterial that can help to address antibiotic resistant infections. Phage therapy can be augmented using CRISPR (clustered regularly interspaced short palindromic repeats) for tailored bacterial killing. This article assesses the potential of CRISPR-enhanced phage therapy as a product that can address antibiotic resistance, focusing on the economic, legal, and regulatory challenges to its development and availability

U2 - https://doi.org/10.1093/jlb/lsad030

DO - https://doi.org/10.1093/jlb/lsad030

M3 - Journal article

VL - 11

JO - Journal of Law and the Biosciences

JF - Journal of Law and the Biosciences

SN - 2053-9711

IS - 1

ER -

ID: 307030282